Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy.

For the treatment of infectious diseases, cancer and allergy, the directed induction of an appropriate immune response is the ultimate goal. Therefore, with the development of pure, often very small proteins, peptides or DNA by molecular biology techniques, the research for suitable adjuvants or delivery systems became increasingly important. Particle formulations are made of a variety of materials, including lipids, proteins or amino acids, polysaccharides, polyacrylic substances or organic acids. Microparticles serve as vehicles and provide a depot for the entrapped or coupled antigen. The release occurs in a pulsatile or continuous manner, a feature, which is well controllable for many particulate systems. Particles attract antigen presenting cells to the administration site, thereby guaranteeing the efficient presentation of the antigen to the immune system. Importantly, particles also protect the entrapped substance. This is especially necessary after oral application to avoid gastric or tryptic breakdown. In this article, the design and construction of different antigen delivery systems and their immune effects, with special focus on the suitability for allergy treatment, are discussed.

[1]  K. Maloy,et al.  Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. , 1993, Immunology.

[2]  J. G. Michael,et al.  Abrogation of oral tolerance by feeding encapsulated antigen. , 2000, Cellular immunology.

[3]  J. Iida,et al.  Stimulation of non-specific host resistance against Sendai virus and Escherichia coli infections by chitin derivatives in mice. , 1987, Vaccine.

[4]  A. Florence,et al.  A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: potential uses in drug and vaccine delivery. , 1995, Journal of drug targeting.

[5]  A. Hensel,et al.  New strategies for combination vaccines based on the extended recombinant bacterial ghost system. , 1999, Vaccine.

[6]  J L Cleland,et al.  Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. , 1996, Journal of pharmaceutical sciences.

[7]  Postlethwait Rw,et al.  A new synthetic absorbable suture. , 1975 .

[8]  M. Maeda,et al.  Sustained release of human growth hormone (hGH) from collagen film and evaluation of effect on wound healing in db/db mice. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[9]  I. Barr,et al.  ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.

[10]  P. Couvreur,et al.  [Oral tolerance induced by poly (lactide-co-glycolide) containing B lactoglobulin]. , 2002, Annales pharmaceutiques francaises.

[11]  M. Audícana,et al.  Systemic reactions to immunotherapy: influence of composition and manufacturer , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  Constancis,et al.  Macromolecular Colloids of Diblock Poly(amino acids) That Bind Insulin. , 1999, Journal of colloid and interface science.

[13]  B. Angelini,et al.  Efficacy and safety of oral immunotherapy with short ragweed extract. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  H. Sung,et al.  Genipin-crosslinked gelatin microspheres as a drug carrier for intramuscular administration: in vitro and in vivo studies. , 2003, Journal of biomedical materials research. Part A.

[15]  T Ochiya,et al.  Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions. , 2001, Biochemical and biophysical research communications.

[16]  E. C. Beuvery,et al.  On the structure of immune-stimulating saponin-lipid complexes (iscoms). , 1991, Biochimica et biophysica acta.

[17]  W. A. Taylor,et al.  Adjuvant and suppressive effects of Grass Conjuvac and other alginate conjugates on IgG and IgE antibody responses in mice. , 1981, Immunology.

[18]  S. K. Das,et al.  Physicochemical Characterization of Influenza Viral Vaccine Loaded Surfactant Vesicles , 2003, Drug delivery.

[19]  U. Brunk,et al.  Biodegradable microspheres. VII: Alterations in mouse liver morphology after intravenous administration of polyacryl starch microparticles with different biodegradability. , 1988, Journal of pharmaceutical sciences.

[20]  A. Mowat,et al.  Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin‐4 or interferon‐γ , 1998, Immunology.

[21]  N. Arora,et al.  Allergens entrapped in liposomes reduce allergenicity and induce immunogenicity on repeated injections in mice. , 1990, International archives of allergy and applied immunology.

[22]  C. Sturesson,et al.  Comparison of poly(acryl starch) and poly(lactide-co-glycolide) microspheres as drug delivery system for a rotavirus vaccine. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[23]  W. Lubitz,et al.  Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[24]  P. Artursson,et al.  Microparticles as potentially orally active immunological adjuvants. , 1989, Vaccine.

[25]  G. Sprott,et al.  Archaeobacterial ether lipid liposomes as vaccine adjuvants. , 2003, Methods in enzymology.

[26]  J. Mizuguchi,et al.  Ovalbumin-liposome conjugate induces IgG but not IgE antibody production. , 1996, International archives of allergy and immunology.

[27]  K. Maloy,et al.  Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS , 1995, European journal of immunology.

[28]  B. García,et al.  Liposome‐entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1‐year double‐blind, placebo‐controlled trial on inflammation, bronchial hyper‐responsiveness and immediate and late bronchial responses to the allergen , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  A. Bernkop‐Schnürch,et al.  Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[30]  S. Correa,et al.  Early events associated to the oral co-administration of type II collagen and chitosan: induction of anti-inflammatory cytokines. , 2004, International immunology.

[31]  Hojo,et al.  Protein release from collagen matrices. , 1998, Advanced drug delivery reviews.

[32]  A. Coombes,et al.  Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. , 1999, Vaccine.

[33]  I Saiki,et al.  Immunological activity of chitin and its derivatives. , 1984, Vaccine.

[34]  T. Kissel,et al.  Biodegradable microspheres containing influenza A vaccine: immune response in mice. , 1999, Vaccine.

[35]  Joseph A. Zasadzinski,et al.  Encapsulation of bilayer vesicles by self-assembly , 1997, nature.

[36]  A. Bernkop‐Schnürch,et al.  Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[38]  T. Platts-Mills,et al.  The Immune Response to Intrinsic and Extrinsic Allergens: Determinants of Allergic Disease , 2002, International Archives of Allergy and Immunology.

[39]  J. Clegg,et al.  Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. , 1997, Vaccine.

[40]  Leaf Huang,et al.  Potentiation of cationic liposome-mediated gene delivery by polycations. , 1996, Biochemistry.

[41]  A. Bernkop‐Schnürch,et al.  Thiolated chitosans. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  J. Wilschut,et al.  Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs , 2002, Bioscience reports.

[43]  E. Untersmayr,et al.  M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. , 2004, The Journal of allergy and clinical immunology.

[44]  H. Sah,et al.  Prolonged Immune Response Evoked by a Single Subcutaneous Injection of Microcapsules Having a Monophasic Antigen Release , 1996, The Journal of pharmacy and pharmacology.

[45]  M. Patarroyo,et al.  Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. , 2001, Vaccine.

[46]  T. Kissel,et al.  Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: is the erosion controlled by degradation, swelling or diffusion? , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[47]  B. Gander,et al.  Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[48]  E. Pastorello,et al.  A double‐blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac®) in patients with perennial rhinitis , 1989 .

[49]  C. Hunter,et al.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.

[50]  J. Brewer,et al.  The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. , 1992, Immunology.

[51]  G. Patel,et al.  In vitro assessment of archaeosome stability for developing oral delivery systems. , 2000, International journal of pharmaceutics.

[52]  C. Herzog,et al.  Mucosal antibody response induced with a nasal virosome-based influenza vaccine. , 2003, Vaccine.

[53]  H. HogenEsch,et al.  Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. , 2000, Vaccine.

[54]  A. Jegerlehner,et al.  Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles1 , 2002, The Journal of Immunology.

[55]  M. Groves,et al.  Gelatin Behaviour in Dilute Aqueous Solution: Designing a Nanoparticulate Formulation , 1999, The Journal of pharmacy and pharmacology.

[56]  M. Hashida,et al.  An application of water-in-oil and gelatin-microsphere-in-oil emulsions to specific delivery of anticancer agent into stomach lymphatics , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[57]  D. Crommelin,et al.  Liposomes and ISCOMS as vaccine formulations. , 1995, Biochimica et biophysica acta.

[58]  J. Mcginity,et al.  Preparation and evaluation of a sustained morphine delivery system in rats , 1978, Pharmacology Biochemistry and Behavior.

[59]  Daniel G. Anderson,et al.  pH-Triggered Microparticles for Peptide Vaccination1 , 2004, The Journal of Immunology.

[60]  Manmohan J. Singh,et al.  Advances in vaccine adjuvants , 1999, Nature Biotechnology.

[61]  W. Mark Saltzman,et al.  Intracranial Delivery of Recombinant Nerve Growth Factor: Release Kinetics and Protein Distribution for Three Delivery Systems , 1999, Pharmaceutical Research.

[62]  R. Valenta,et al.  Carbohydrate‐based particles: a new adjuvant for allergen‐specific immunotherapy , 2002, Immunology.

[63]  W. Zollinger,et al.  GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. , 1993, Vaccine.

[64]  J L Cleland,et al.  Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. , 1998, Journal of pharmaceutical sciences.

[65]  Per Artursson,et al.  Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells , 1996, Pharmaceutical Research.

[66]  R. Crowther,et al.  Hepatitis B virus core particles as epitope carriers. , 1995, Intervirology.

[67]  J. Pappo,et al.  Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells , 1995, Cell and Tissue Research.

[68]  Q. Myrvik,et al.  Oral Administration of Chitin Down-Regulates Serum IgE Levels and Lung Eosinophilia in the Allergic Mouse1 , 2000, The Journal of Immunology.

[69]  B. García,et al.  Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. , 2002, The Journal of allergy and clinical immunology.

[70]  D. O'hagan,et al.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. , 1994, Immunology.

[71]  C A Evans,et al.  The vesosome-- a multicompartment drug delivery vehicle. , 2004, Current medicinal chemistry.

[72]  R. Glück Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). , 1999, Vaccine.

[73]  S. Davis,et al.  Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. , 1993, Vaccine.

[74]  R. Wirtz,et al.  Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. , 1988, Science.

[75]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[76]  F Ambrosch,et al.  Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. , 1997, Vaccine.

[77]  G. Patel,et al.  Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and Alum , 2000, Infection and Immunity.

[78]  R. Glück Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. , 1992, Vaccine.

[79]  E. Untersmayr,et al.  Functionalisation of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes. , 2004, Biochemical and biophysical research communications.

[80]  B. T. Bennett,et al.  Review of Polyclonal Antibody Production Procedures in Mammals and Poultry. , 1995, ILAR journal.

[81]  I. Azuma,et al.  Adjuvant activity of chitin derivatives in mice and guinea-pigs. , 1985, Vaccine.

[82]  Patel Gb,et al.  Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. , 1999 .

[83]  S. Leucuţa,et al.  Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization. , 2003, Journal of microencapsulation.

[84]  A. Jegerlehner,et al.  Virus-Like Particles as a Modular System for Novel Vaccines , 2003, Intervirology.

[85]  N. Valiante,et al.  Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.

[86]  S. Ahlstedt,et al.  Clinical and Immunological Effects of Oral Immunotherapy with a Standardized Birch Pollen Extract , 1986, Allergy.

[87]  C Leclerc,et al.  Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. , 1995, Vaccine.

[88]  R. Mannino,et al.  Lipid matrix-based vaccines for mucosal and systemic immunization. , 1995, Pharmaceutical biotechnology.

[89]  E. Untersmayr,et al.  Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. , 2005, Vaccine.

[90]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.

[91]  Y. Ikada,et al.  Usefulness of microspheres composed of gelatin with various cross-linking density , 2003 .

[92]  J. Cleland Single-administration vaccines: controlled-release technology to mimic repeated immunizations. , 1999, Trends in biotechnology.

[93]  D. O'hagan,et al.  Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae. , 1995, Vaccine.

[94]  R. Lockey,et al.  Genetic Vaccines and Therapy , 2003 .

[95]  G. Reid Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. , 1992, Vaccine.

[96]  J. G. Michael,et al.  Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. , 1997, The Journal of allergy and clinical immunology.

[97]  G. Cevc,et al.  Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. , 1998, Vaccine.

[98]  H E Junginger,et al.  Chitosan and its derivatives in mucosal drug and vaccine delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[99]  J. Brewer,et al.  Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant-driven IgG2a production independent of MHC control. , 1994, Vaccine.

[100]  A. Asghar,et al.  Chemical, biochemical, functional, and nutritional characteristics of collagen in food systems. , 1982, Advances in food research.

[101]  U. Bläsi,et al.  Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E , 1990, Journal of bacteriology.

[102]  M. Villacrés-Eriksson,et al.  In vitro activation of antigen‐presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids , 1996, Clinical and experimental immunology.

[103]  I. Sjöholm,et al.  Extracellular Antigens from Salmonella enteritidis Induce Effective Immune Response in Mice after Oral Vaccination , 2002, Infection and Immunity.

[104]  M. Taneichi,et al.  Antigen–Specific, IgE–Selective Unresponsiveness Induced by Antigen–Liposome Conjugates , 1999, International Archives of Allergy and Immunology.

[105]  M. Villalba,et al.  Encapsulation of Ole e 1 in biodegradable microparticles induces Th1 response in mice: a potential vaccine for allergy. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[106]  M. Maeda,et al.  Microstructure and release characteristics of the minipellet, a collagen-based drug delivery system for controlled release of protein drugs. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[107]  A. Klein,et al.  Skin filling. Collagen and other injectables of the skin. , 2001, Dermatologic clinics.

[108]  P. Artursson,et al.  Encapsulation of rotavirus into poly(lactide-co-glycolide) microspheres. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[109]  Sharon Ac,et al.  Development of drug delivery systems for use in treatment of narcotic addiction. , 1981 .

[110]  I. Sjöholm,et al.  Acrylic microspheres in vivo V: Immunological properties of immobilized asparaginase in microparticles. , 1982, Journal of pharmaceutical sciences.

[111]  X. Wu,et al.  Preparation and characterization of agarose hydrogel nanoparticles for protein and peptide drug delivery. , 1997, Pharmaceutical development and technology.

[112]  J. Schlom,et al.  Oral immunization with enterocoated microbeads induces antigen-specific cytolytic T-cell responses. , 1998, Cellular immunology.

[113]  D. Gopinath,et al.  Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications. , 2004, International journal of pharmaceutics.

[114]  L. Degling,et al.  Biodegradable microspheres. XVIII: The adjuvant effect of polyacryl starch microparticles with conjugated human serum albumin. , 1995, Vaccine.

[115]  K. Fujioka,et al.  Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid. , 2001, Vaccine.

[116]  L. Faccioli,et al.  Role of Trehalose Dimycolate in Recruitment of Cells and Modulation of Production of Cytokines and NO in Tuberculosis , 2001, Infection and Immunity.

[117]  A. Kapp,et al.  Aluminium‐induced granulomas after inaccurate intradermal hyposensitization injections of aluminium‐adsorbed depot preparations , 2000, Allergy.

[118]  H. Junginger,et al.  Transport of Chitosan Microparticles for Mucosal Vaccine Delivery in a Human Intestinal M-cell Model , 2002, Journal of drug targeting.

[119]  T. Ochiya,et al.  Atelocollagen for protein and gene delivery. , 2003, Advanced drug delivery reviews.

[120]  L. Ambrosio,et al.  Chitosan-mediated stimulation of macrophage function. , 1994, Biomaterials.

[121]  M. Paternostre,et al.  Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse. , 1998, Journal of drug targeting.

[122]  J. Pedraz,et al.  Preliminary Assessment of the Immune Response to Olea europaea Pollen Extracts Encapsulated into PLGA Microspheres , 2001, Pharmaceutical development and technology.

[123]  A. Zimmer,et al.  Antisense delivery using protamine-oligonucleotide particles. , 2000, Nucleic acids research.

[124]  J. Kost,et al.  Chemically-modified polysaccharides for enzymatically-controlled oral drug delivery. , 1990, Biomaterials.

[125]  G. Cevc,et al.  Transdermal immunization with large proteins by means of ultradeformable drug carriers , 1995, European journal of immunology.

[126]  R. Aalberse,et al.  Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. , 1983, Journal of immunology.

[127]  G. Gleich,et al.  Immunotherapy with short ragweed fraction A:D-glutamic acid:D-lysine polymer in ragweed hay fever. , 1981, The Journal of allergy and clinical immunology.

[128]  A. Shahzamani,et al.  A month–long effect from a single injection of microencapsulated human growth hormone , 1996, Nature Medicine.

[129]  J. Sadoff,et al.  Preparation of proteosome-based vaccines. Correlation of immunogenicity with physical characteristics. , 1990, Journal of immunological methods.

[130]  D. Gopinath,et al.  1-O-Alkylglycerol vesicles (Algosomes): their formation and characterization. , 2002, International journal of pharmaceutics.

[131]  J. Mcghee,et al.  Biodegradable microspheres as a vaccine delivery system. , 1991, Molecular immunology.

[132]  J L Pedraz,et al.  Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[133]  Wang,et al.  Targeting immune response induction with cochleate and liposome-based vaccines. , 1998, Advanced drug delivery reviews.

[134]  A. Coombes,et al.  Resorbable synthetic polymers as replacements for bone graft. , 1994, Clinical materials.

[135]  W. Shen,et al.  Poly(L-lysine) has different membrane transport and drug-carrier properties when complexed with heparin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[136]  K. Goracinova,et al.  Biodistribution of 131I-BSA loaded gelatin microspheres after peroral application to BALB/c mice--particle size study. , 2003, Acta pharmaceutica.

[137]  R. Rowland,et al.  The stability of liposomes in vitro to pH, bile salts and pancreatic lipase. , 1980, Biochimica et biophysica acta.

[138]  T. Miyata,et al.  Collagen as a biomaterial. , 1974, Annual review of biophysics and bioengineering.

[139]  F. Lechner,et al.  Cross‐presentation of virus‐like particles by skin‐derived CD8– dendritic cells: a dispensable role for TAP , 2002, European journal of immunology.

[140]  A. Zimmer,et al.  Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles. , 2001, Biochimica et biophysica acta.

[141]  Robert T. Chen,et al.  Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. , 2002, Pediatrics.

[142]  A. Coombes,et al.  Resorbable polymeric microspheres for drug delivery--production and simultaneous surface modification using PEO-PPO surfactants. , 1994, Biomaterials.

[143]  J. Eldridge,et al.  Biodegradable microspheres: vaccine delivery system for oral immunization. , 1989, Current topics in microbiology and immunology.

[144]  A. Zoss,et al.  Alum-ragweed precipitate: Preparation and clinical investigation: Preliminary report , 1937 .

[145]  R. F. Cook,et al.  Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. , 1994, Vaccine.

[146]  C. Fossum,et al.  Antigen‐Specific Increases in the Number of Splenocytes Expressing MHC Class II Molecules Following Restimulation with Antigen in Various Physical Forms , 1992, Scandinavian journal of immunology.

[147]  I. Sjöholm,et al.  Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. , 2002, Vaccine.

[148]  M. Villalba,et al.  Biodegradable poly (DL-lactide glycolide) microparticles as a vehicle for allergen-specific vaccines: a study performed with Ole e 1, the main allergen of olive pollen. , 2002, Journal of immunological methods.

[149]  G. Cevc,et al.  Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. , 1992, Anesthesia and analgesia.

[150]  F. Silver,et al.  Collagen deposition during wound repair. , 1985, Scanning electron microscopy.

[151]  J L Cleland,et al.  Encapsulation and stabilization of nerve growth factor into poly(lactic-co-glycolic) acid microspheres. , 2001, Journal of pharmaceutical sciences.

[152]  S. Fürst-Ladani,et al.  Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells. , 2000, Journal of biotechnology.

[153]  M. Brandon,et al.  The application of biodegradable collagen minipellets as vaccine delivery vehicles in mice and sheep. , 2001, Vaccine.

[154]  R. Lindmark,et al.  Immobilization of proteins by entrapment in polyacrylamide microbeads. , 1982, Journal of immunological methods.

[155]  M. Pizza,et al.  Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. , 2004, Journal of pharmaceutical sciences.

[156]  K. Goracinova,et al.  Biodistribution studies of BSA loaded gelatin microspheres after peroral application. , 2002, International journal of pharmaceutics.

[157]  Q. Myrvik,et al.  Th1 Adjuvant N-Acetyl-d-Glucosamine Polymer Up-Regulates Th1 Immunity but Down-Regulates Th2 Immunity against a Mycobacterial Protein (MPB-59) in Interleukin-10-Knockout and Wild-Type Mice , 2001, Infection and Immunity.

[158]  P. G. Seferian,et al.  Immune stimulating activity of two new chitosan containing adjuvant formulations. , 2000, Vaccine.

[159]  H E Junginger,et al.  Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. , 2001, Biomaterials.

[160]  G. Patel,et al.  Archaeosomes as novel antigen delivery systems. , 1997, FEMS microbiology letters.

[161]  R. Porsche,et al.  Allergy to protamine sulfate. , 1999, Heart & lung : the journal of critical care.

[162]  A. Coombes,et al.  Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. , 1995, Vaccine.

[163]  G. Barratt,et al.  Optimization and characterization of freeze‐dried multilamellar liposomes incorporating different standardized allergen extracts , 1994, Allergy.

[164]  J. G. Michael,et al.  Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[165]  Y. Y. Wang,et al.  Effect of liposomes and niosomes on skin permeation of enoxacin. , 2001, International journal of pharmaceutics.

[166]  E. Untersmayr,et al.  Allergen‐loaded biodegradable poly(d,l‐lactic‐co‐glycolic) acid nanoparticles down‐regulate an ongoing Th2 response in the BALB/c mouse model , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[167]  W. Zollinger,et al.  Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants , 1988, The Journal of experimental medicine.

[168]  D. Tomé,et al.  Microsphere entrapped bee-venom phospholipase A2 retains specific IgE binding capacity: a possible use for oral specific immunotherapy , 2002, Journal of microencapsulation.

[169]  B. Jarzab,et al.  Corticotropin releasing hormone (CRH) increases beta-endorphin (beta-end like) concentration in cerebrospinal fluid of rats with vasospasm following subarachnoid hemorrhage. , 1999, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[170]  K. Lima,et al.  Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system. , 1999, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[171]  D. Vercelli Molecular regulation of the IgE immune response , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[172]  A. Rathinavelu,et al.  Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[173]  N. Georgakis,et al.  The use of alginate adjuvant as a vehicle in the treatment of ragweed pollinosis. , 1967, Annals of allergy.

[174]  G. Trinchieri,et al.  Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. , 1997, Cytokine.

[175]  A. Schaffner,et al.  Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. , 1982, The Journal of clinical investigation.

[176]  N. Wang,et al.  Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. , 1998, Journal of microencapsulation.

[177]  D T O'Hagan,et al.  Microparticles for intranasal immunization. , 2001, Advanced drug delivery reviews.

[178]  B. Hirst,et al.  Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. , 1993, Journal of drug targeting.

[179]  H. Junginger,et al.  Niosomes as a novel peroral vaccine delivery system. , 1999, International journal of pharmaceutics.

[180]  A. Sjölander,et al.  Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. , 1997, Cellular immunology.

[181]  X M Li,et al.  Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. , 1996, Vaccine.

[182]  J. Gallo,et al.  Receptor-Mediated Magnetic Carriers: Basis for Targeting , 1988, Pharmaceutical Research.

[183]  Q. Myrvik,et al.  Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. , 1997, Journal of immunology.

[184]  J. Lamb,et al.  Kinetics and mode of peptide delivery via the respiratory mucosa determine the outcome of activation versus TH2 immunity in allergic inflammation of the airways. , 2002, The Journal of allergy and clinical immunology.

[185]  N. Arora,et al.  Liposomes as vehicle for allergen presentation in the immunotherapy of allergic diseases , 1991, Allergy.

[186]  W. Lubitz,et al.  Sealed bacterial ghosts--novel targeting vehicles for advanced drug delivery of water-soluble substances. , 2003, Journal of drug targeting.

[187]  F. Eko,et al.  Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. , 2003, Vaccine.

[188]  R. Djukanović,et al.  Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. , 2000, American journal of respiratory and critical care medicine.

[189]  S. Cryz,et al.  Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. , 1992, The Journal of clinical investigation.

[190]  W. A. Taylor,et al.  Grass Conjuvac. II. Pro-inflammatory activity and potential for inducing hypersensitivity. , 1984, International archives of allergy and applied immunology.

[191]  N. Wang,et al.  A novel biodegradable system based on gelatin nanoparticles and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery. , 1997, Journal of pharmaceutical sciences.

[192]  E. Pastorello,et al.  A double‐blind, placebo‐controlled study of immunotherapy with an alginate‐conjugated extract of Parietaria Judaica in patients with Parietaria hay fever , 1994, Allergy.

[193]  I. Kwon,et al.  Novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microspheres. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[194]  P. Drewes,et al.  Radioimmunoassay of polyacrylamide , 1978, Experientia.

[195]  I. Kwon,et al.  Protective Immunity of Microsphere-Based Mucosal Vaccines against Lethal Intranasal Challenge withStreptococcus pneumoniae , 1999, Infection and Immunity.

[196]  D. Henderson,et al.  Immunogenicity in guinea pigs and tolerance in grass pollen-sensitive volunteers of enteric-coated grass pollen allergens. , 1987, International archives of allergy and applied immunology.

[197]  A. Kingsman,et al.  Yeast Retrotransposon Particles as Antigen Delivery Systems , 1995, Annals of the New York Academy of Sciences.

[198]  P. Strong,et al.  Intranasal application of chitin microparticles down‐regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[199]  A. Jegerlehner,et al.  A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. , 2002, Vaccine.

[200]  S. Sad,et al.  Archaeosomes Induce Long-Term CD8+ Cytotoxic T Cell Response to Entrapped Soluble Protein by the Exogenous Cytosolic Pathway, in the Absence of CD4+ T Cell Help1 , 2000, The Journal of Immunology.

[201]  David R. Olsen,et al.  Recombinant collagen and gelatin for drug delivery. , 2003, Advanced drug delivery reviews.

[202]  J. Cleland Solvent Evaporation Processes for the Production of Controlled Release Biodegradable Microsphere Formulations for Therapeutics and Vaccines , 1998, Biotechnology progress.

[203]  Joon-Lin Chew,et al.  Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. , 2003, Vaccine.

[204]  T. Miyata,et al.  Collagen as a Vehicle for Drug Delivery , 1973 .

[205]  J. Eldridge,et al.  Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. , 1989, Advances in experimental medicine and biology.

[206]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[207]  Y. Rahman,et al.  Liposomes containing chelating agents. Cellular penetration and a possible mechanism of metal removal , 1975, The Journal of cell biology.

[208]  G. H. Coombs,et al.  Non‐ionic surfactant vesicles, niosomes, as a delivery system for the anti‐leishmanial drug, sodium stibogluconate , 1986, The Journal of pharmacy and pharmacology.

[209]  H Lennernäs,et al.  Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[210]  M. Villacrés-Eriksson,et al.  Influence of Quillaja saponaria Triterpenoid Content on the Immunomodulatory Capacity of Epstein–Barr Virus Iscoms , 1997, Scandinavian journal of immunology.

[211]  M. Plante,et al.  A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. , 2003, Vaccine.

[212]  Taylor Wa,et al.  Grass conjuvac. I. Immunogenicity in rabbits, guinea pigs and rats. , 1983 .

[213]  S. Davis,et al.  Controlled release microparticles for vaccine development. , 1991, Vaccine.

[214]  T. Ochiya,et al.  New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet , 1999, Nature Medicine.

[215]  J. Szebeni,et al.  Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. , 2001, Critical reviews in therapeutic drug carrier systems.

[216]  Y. Ikada,et al.  Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. , 1988, Journal of biomedical materials research.

[217]  W. Lubitz Bacterial ghosts as carrier and targeting systems , 2001, Expert opinion on biological therapy.

[218]  A. Pfeifer,et al.  Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres. , 2000, Vaccine.

[219]  V. N. Fedoseeva,et al.  Properties of liposomal allergens ofNeisseria perflava , 1982, Bulletin of Experimental Biology and Medicine.

[220]  R. Gupta,et al.  Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens. , 1996, Vaccine.

[221]  R. Mannino,et al.  Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization. , 1994, AIDS research and human retroviruses.

[222]  W. Lubitz,et al.  Bacterial Ghosts Are an Efficient Delivery System for DNA Vaccines1 , 2004, The Journal of Immunology.

[223]  Yumin Du,et al.  Enzymic preparation of water-soluble chitosan and their antitumor activity. , 2002, International journal of biological macromolecules.

[224]  Deog-Yong Lee,et al.  Chitosan and D-glucosamine induce expression of Th1 cytokine genes in porcine spleen cells. , 2002, The Journal of veterinary medical science.

[225]  L. Baillie,et al.  Biodegradable Microparticles with Different Release Profiles: Effect on the Immune Response After a Single Administration via Intranasal and Intramuscular Routes , 2000, The Journal of pharmacy and pharmacology.

[226]  R. Muzzarelli,et al.  Reconstruction of parodontal tissue with chitosan. , 1989, Biomaterials.

[227]  Abdelwahab Omri,et al.  Short-Term Repeated-Dose Toxicity Profile of Archaeosomes Administered to Mice via Intravenous and Oral Routes , 2003, International journal of toxicology.

[228]  D. Crommelin,et al.  Liposomes and ISCOMs. , 2003, Vaccine.

[229]  S. Sad,et al.  Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. , 2003, Cancer research.

[230]  C. Choquet,et al.  Stability of pressure-extruded liposomes made from archaeobacterial ether lipids , 1994, Applied Microbiology and Biotechnology.

[231]  F. Raffi,et al.  N-acetyl-β-D-Glucosaminidase (NAG) isoenzymes release from human monocyte-derived macrophages in response to zymosan and human recombinant interferon-γ , 1991 .

[232]  A. McWilliam,et al.  Alveolar Macrophages Bind and Phagocytose Allergen- Containing Pollen Starch Granules Via C-Type Lectin and Integrin Receptors: Implications for Airway Inflammatory Disease1 , 2000, The Journal of Immunology.

[233]  K. Mills,et al.  Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. , 1995, Vaccine.

[234]  J. Mazurkiewicz,et al.  Chimerasome-mediated gene transfer in vitro and in vivo. , 1989, Gene.

[235]  J. Wilschut,et al.  VIROSOMES IN VACCINE DEVELOPMENT: INDUCTION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY WITH VIROSOME-ENCAPSULATED PROTEIN ANTIGENS , 2002, Journal of liposome research.

[236]  Y. Ikada,et al.  Potentiality of gelatin microsphere as immunological adjuvant. , 1995, Vaccine.

[237]  P. Artursson,et al.  Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement , 1997, Pharmaceutical Research.

[238]  J. Pappo,et al.  Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake. , 1989, Clinical and experimental immunology.

[239]  J. Berzofsky,et al.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs , 1990, Nature.